Arbor Pharmaceuticals and its partners have multiple projects under various stages of development. We develop both new chemical entities as well as already approved molecules for new indications or improved dosage forms. Our research scientists have extensive experience in clinical development and work collaboratively with partners and the FDA to develop new therapeutic options for clinicians. The company has already filed and gained approval on five New Drug Applications (NDAs), in addition to multiple expansions of already approved treatments. Additional products are in late-stage development with anticipated approvals forthcoming as shown below.